Ligand Pharmaceuticals
LGND
257 hedge funds and large institutions have $2.61B invested in Ligand Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 111 increasing their positions, 95 reducing their positions, and 30 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 95
4% more capital invested
Capital invested by funds: $2.52B → $2.61B (+$94.6M)
0.99% less ownership
Funds ownership: 190.24% → 189.26% (-0.99%)
5% less funds holding
Funds holding: 270 → 257 (-13)
13% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 30
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
67% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $36.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$276M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$67.8M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$54.2M |
| 4 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$11.3M |
| 5 |
Renaissance Technologies
New York
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$53.2M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$31.1M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$29.8M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$25.7M |
| 5 |
KI
Kalmar Investments
Greenville,
Delaware
|
-$18M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
276
D.E. Shaw & Co
New York
| – | -$272K | -4,134 | Closed |
|
277
Millennium Management
New York
| – | -$229K | -3,610 | Closed |
|
278
Citadel Advisors
Miami,
Florida
| – | -$218K | -3,312 | Closed |
|
|
AIM
279
Acrospire Investment Management
Chicago,
Illinois
| – | -$132K | -2,082 | Closed |
|
280
VanEck Associates
New York
| – | -$26K | -404 | Closed |
|
|
TRCT
281
Tower Research Capital (TRC)
New York
| – | -$20K | -313 | Closed |
|
|
AA
282
Ancora Advisors
Cleveland,
Ohio
| – | -$15K | -240 | Closed |
|
|
PHK
283
Point72 Hong Kong
Hong Kong
| – | -$13K | -199 | Closed |
|
284
Loomis, Sayles & Company
Boston,
Massachusetts
| – | -$11K | -175 | Closed |
|
|
MMG
285
Monetary Management Group
St Louis,
Missouri
| – | -$10K | -160 | Closed |
|
286
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$197 | +3 | New |
|
|
PFO
287
Pathstone Family Office
Englewood,
New Jersey
| – | +$395 | +6 | New |
|
LGND Hedge Fund Activity: Q1 2017 in Review
257 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2017, worth a combined $2.61B — up 3.8% from $2.52B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of LGND and 26 opened new positions — a net loss of 4 holders — while 95 trimmed existing stakes and 111 added.
The largest buyer was BlackRock, adding an estimated $276M. The largest seller was Wells Fargo, cutting an estimated $53.2M.
- 257 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2017, down from 270 in Q4 2016.
- Funds reported $2.61B of Ligand Pharmaceuticals stock for Q1 2017, up 3.8% quarter-over-quarter.
- 26 funds opened new Ligand Pharmaceuticals positions in Q1 2017 and 30 closed out, a net change of -4 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $276M added.
- The largest Ligand Pharmaceuticals seller in Q1 2017 was Wells Fargo, an estimated $53.2M sold.
Based on aggregated 13F filings for Q1 2017.